These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. Mapara MY; Sykes M J Clin Oncol; 2004 Mar; 22(6):1136-51. PubMed ID: 15020616 [TBL] [Abstract][Full Text] [Related]
8. Developments in cancer immunotherapy. van den Broek M; von Boehmer L; Knuth A Dig Dis; 2010; 28(1):51-6. PubMed ID: 20460890 [TBL] [Abstract][Full Text] [Related]
9. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Mocellin S; Rossi CR; Nitti D Exp Cell Res; 2004 Oct; 299(2):267-78. PubMed ID: 15350526 [TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy: a treatment for the masses. Blattman JN; Greenberg PD Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469 [TBL] [Abstract][Full Text] [Related]
11. Tumor immunity. An overview. Siegel BV Am J Pathol; 1978 Nov; 93(2):515-24. PubMed ID: 717538 [TBL] [Abstract][Full Text] [Related]
12. New possibilities for cancer therapy with advances in cancer immunology. MacLean GD; Longenecker BM Can J Oncol; 1994 Apr; 4(2):249-54. PubMed ID: 7516257 [TBL] [Abstract][Full Text] [Related]
13. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]. Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096 [TBL] [Abstract][Full Text] [Related]
14. Tumor vaccine: current trends in antigen specific immunotherapy. Baral R Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903 [TBL] [Abstract][Full Text] [Related]
15. Immune monitoring of cancer patients undergoing experimental immunotherapy. Shankar G; Salgaller ML Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653 [TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines: an update with special focus on ganglioside antigens. Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591 [TBL] [Abstract][Full Text] [Related]
17. [Immune response and cancer]. El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571 [TBL] [Abstract][Full Text] [Related]
18. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Sensi M; Anichini A Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217 [TBL] [Abstract][Full Text] [Related]
19. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Rosenberg SA Cancer J Sci Am; 1995; 1(2):90-100. PubMed ID: 9166458 [TBL] [Abstract][Full Text] [Related]